Advanced biotechnology · News Analysis
Partial-reprogramming trial is testing eye-treatment safety—not human rejuvenation
A recruiting Phase 1 study will expose 18 people with optic-nerve conditions to an investigational OSK gene therapy. Its first job is safety and tolerability, not proving that aging can be reversed in people.
Human publication approval was recorded July 31, 2026 after source, correction-status, and evidence review.
Evidence box
Early human safety stage
- Study type
- Non-randomized, open-label Phase 1 dose escalation and expansion
- Studied in
- 18 adults aged 40–85 with glaucoma or recent NAION (estimated)
- Publication status
- Recruiting registry; no posted human results
- Outcome type
- Safety, dose-limiting toxicity, laboratory and eye measures
- Development stage
- Phase 1 investigational gene therapy
- Conflicts / funding
- Industry-sponsored by Life Biosciences
- Editorial assessment
- Early; safety question only
- Reporting confidence
- High for registry facts; efficacy unknown
The bottom line
ClinicalTrials.gov lists NCT07290244 as recruiting as of July 31, 2026. The sponsor plans to enroll 18 adults with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy in a single-dose, open-label Phase 1 study of ER-100. The primary outcomes are adverse events, dose-limiting toxicities and safety measurements—not longevity, lifespan or general rejuvenation. (registry source)
Why this matters
ER-100 is one of the first registered human studies to test an approach built around partial epigenetic reprogramming. The therapy uses a modified adeno-associated-virus vector delivered into one eye to carry OCT4, SOX2 and KLF4—OSK—with expression activated by oral doxycycline for eight weeks. Moving this idea into people is a scientific milestone, but an early human trial mainly asks whether the intervention can be administered with acceptable short- and long-term risk.
What researchers are doing
The non-randomized study starts with people who have open-angle glaucoma, using sequential low- and high-dose cohorts with sentinel participants and safety review before escalation. A dose selected from those cohorts is then used in people with recent NAION. The registry estimates 18 participants, ages 40 to 85, and follows early safety through day 112 plus longer-term adverse events and laboratory and eye assessments for five years. There is no placebo arm and no masking.
What the preclinical work found
The best-known precursor paper used OSK—without c-Myc—in mouse retinal ganglion cells. In mouse models of optic-nerve injury, glaucoma and aging, the authors reported axon regeneration, improved visual function and changes toward younger DNA-methylation and gene-expression patterns. An earlier study used cyclic OSKM, including c-Myc, in mice and reported improvements in several age-associated phenotypes. These are different factor sets, delivery systems, models and questions; neither paper supplies human efficacy evidence. (OSK mouse study; OSKM mouse study)
How strong is the evidence?
The human evidence is a registered protocol, not a result. Registration gives useful, time-stamped details about the intended population, intervention and outcomes, but ClinicalTrials.gov explicitly does not review every listed study for scientific validity or government approval. Mouse functional findings make the human safety question worth studying; they do not tell us whether ER-100 will preserve or restore vision in people.
What this does not show
The study is not designed to show longer life, broader healthspan, whole-body age reversal or benefit in healthy adults. Even an acceptable short-term safety profile would not establish effectiveness. An aging-clock movement, if one were later observed, would remain a biomarker unless linked to validated clinical benefit.
Safety and conflicts
ER-100 is an investigational AAV-based gene therapy delivered by intravitreal injection and paired with systemic doxycycline. The protocol monitors ocular inflammation, pressure, visual measures, laboratory values, vector shedding and delayed adverse events. Life Biosciences sponsors the trial. Several authors of the 2020 mouse paper disclosed equity, patents or advisory relationships involving Life Biosciences, Iduna Therapeutics or other biotechnology companies; that does not invalidate the work, but it matters when interpreting the path from laboratory result to commercial program. (disclosures)
What happens next
The most informative near-term evidence will be transparent enrollment and safety reporting, followed by complete results that distinguish adverse events from exploratory visual-function signals. A later controlled study would be needed to estimate efficacy. Claims about human rejuvenation would require much broader evidence than this eye-disease safety trial can provide.
Primary and authoritative sources
Sources, roles and limits
- ClinicalTrials.gov record NCT07290244
- Identifier
- NCT07290244
- Role
- Primary registry
- Limitation
- A registry describes a sponsor-submitted protocol; listing is not government validation and no results are posted.
- Checked
- 2026-07-31 · No correction or retraction identified in the canonical record as checked
- Lu et al., Reprogramming to recover youthful epigenetic information and restore vision
- Identifier
- DOI:10.1038/s41586-020-2975-4 · PMID:33268865
- Role
- Primary preclinical context
- Limitation
- Mouse retinal and optic-nerve experiments do not establish safety or benefit in people.
- Checked
- 2026-07-31 · No correction or retraction relationship found in Crossref/PubMed as checked
- Ocampo et al., In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming
- Identifier
- DOI:10.1016/j.cell.2016.11.052 · PMID:27984723
- Role
- Primary preclinical context
- Limitation
- Cyclic OSKM findings came from a premature-aging mouse model and older wild-type mice, not humans.
- Checked
- 2026-07-31 · No correction or retraction relationship found in Crossref/PubMed as checked
Connected topics
Continue through the knowledge system
Disclosures and history
- July 30, 2026 — three-pass research, evidence review and AI-assisted prose draft completed.
- July 31, 2026 — human publication approval recorded; source and correction status rechecked.
- Corrections: none as of publication.